Clinical breast cancer subtypes are represented by HER2+, hormone-responsive (also known as “hormone receptor-positive”, “hormone responsive” or “luminal” tumors), and triple-negative (negative for the expression of estrogen receptor, progesterone receptor, and HER2) [reviewed in (33, 34)]. Here, ERBB2 is linked to breast carcinoma.